AmberGen

What AmberGen does

AmberGen is a privately held, Boston-area biotechnology tools company founded in 1993 to commercialize photocleavable chemistry developed in Professor Kenneth Rothschild's laboratory at Boston University. Its core platform is the patented Miralys MALDI-IHC (Matrix-Assisted Laser Desorption/Ionization Immunohistochemistry) spatial biology imaging system, which uses Photocleavable Mass Tags (PCMTs) — peptide mass-tags attached to antibodies via photocleavable linkers — to enable simultaneous MALDI-MS detection of up to 150+ intact protein biomarkers in a single 45-minute scan, without iterative cycling. The platform is compatible with Bruker rapifleX and timsTOF fleX MALDI-MS instruments and works on both fresh frozen and FFPE tissue, supporting correlative immunofluorescence through optional dual-label probes and combining with native multiomic imaging of unlabeled metabolites, lipids, glycans, and small-molecule drugs on the same tissue section.

AmberGen monetizes the platform through three primary channels: (1) reagent sales — Miralys Probes, Miralys Panels (TurboPlex pre-mixed and VersaPlex configurable formats), Miralys Starter Kits (UV light box, 6-plex validation probes, FFPE slides, and complementary application-scientist onboarding), and Miralys Antibody Conjugation Kits covering 100 PCMT codes; (2) full-service MaxOmic Laboratory multiomic spatial biology imaging and analysis on a fee-for-service basis; and (3) technology licensing of its PC-Biotin, PC-Phosphoramidites, and PC-Linker chemistries to OEM partners including SomaLogic (now Standard BioTools), Promega, Thermo Fisher Scientific, Glen Research, and Link Technologies. Distribution is a hybrid direct/distributor model — direct sales to pharma, biotech, and academic core facilities in North America and globally, with regional distributors in Japan, Korea, Australia, and the UK, plus research-services marketplaces (ScienceExchange, Scientist.com) and a Miralys-enabled service-lab network at MTAC (Washington University), TU Wien, UT Austin, and the University of Victoria.

The company has been non-dilutively financed through approximately $11.5M of NIH SBIR grants across NIA, NCI, NIAID, and NIGMS, and accepted a strategic minority investment from Bruker Corporation in April 2022 alongside additional MassVentures-backed funding rounds of $100K (June 2022) and $200K (May 2023). Customer concentration is diversified across academic translational centers, pharma/biotech drug development teams, and reagent OEM licensees; segment focus spans neuroscience, immuno-oncology, and clinical pathology applications.

Name

AmberGen

Legal name

Ambergen Inc.

Website

https://ambergen.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

AmberGen commercializes the patented Miralys MALDI-IHC spatial biology platform, using Photocleavable Mass Tag chemistry to image 150+ proteins, metabolites, lipids, glycans, and drugs on a single tissue section, serving academic core facilities, pharma/biotech drug developers, and diagnostic reagent licensees worldwide.

Ownership category

akta.pro rank

Product category

Spatial Biology Imaging

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

akta.pro secondary industries

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Proteomics & Mass Spectrometry Services (HLAGANAB)

Keywords

• Spatial biology imaging
• Mass spectrometry reagents
• Photocleavable mass tags
• Multiplex immunohistochemistry
• Drug colocalization imaging

Headquarters

HQ city

Billerica

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Miralys Reagent Sales: Sale of Miralys imaging reagents including photocleavable mass-tag probes, pre-configured panels (TurboPlex™ pre-mixed and VersaPlex™ configurable formats), and antibody conjugation kits. Reagents are sold directly and through distributors in Japan, Korea, Australia, and the UK.
2. MaxOmic Laboratory Services: AmberGen's full-service MaxOmic™ Laboratory provides multiomic spatial biology imaging and analysis as a service, including spatial proteomics, lipidomics, glycomics, metabolomics, and pharma imaging on the same sample. Results are delivered with a detailed project report including descriptive statistics, pairwise colocalization analysis, clustering analysis, and thumbnail grid images.
3. Technology Licensing: Licensing of AmberGen's photocleavable technology (PC-biotin phosphoramidites, PC-Linkers) to third-party reagent companies such as SomaLogic (for the SomaScan proteomics platform), Promega (fluorescent tRNA products), Thermo-Fisher (PC-Biotin-NHS), Glen Research (phosphoramidite DNA-labeling reagents), and Link Technologies (European distribution).
4. Starter Kits and Training Services: One-time sale of Miralys Starter Kits (UV photocleavage light box, 6-plex validation probe mix, pre-stained and unstained FFPE tissue slides) bundled with complimentary onboarding videoconferences and follow-up image review sessions. Additional on-site training sessions available for purchase.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels5 records

Core offering

AmberGen develops and sells the Miralys MALDI-IHC spatial biology imaging platform, including Photocleavable Mass Tag (PCMT) antibody probes, pre-configured panels, antibody conjugation kits, and starter kits that enable ultra-high-plex (150+ proteins) imaging of tissues on standard MALDI mass spectrometers. The company also operates the MaxOmic Laboratory, a fee-for-service offering that delivers full-service multiomic spatial imaging and analysis (proteins, lipids, glycans, metabolites, transcripts, and drugs on the same sample).

Product overview

AmberGen offers the Miralys platform as its core product line for spatial biology research. The platform centers on patented Photocleavable Mass Tag (PCMT) technology that enables hyperplex MALDI-IHC (Immunohistochemistry) imaging of up to 150+ intact proteins in 45 minutes on a single tissue sample. The product portfolio includes: Miralys Probes (photocleavable mass-tag antibody reagents available as standard or dual-labeled), Miralys Panels (curated collections in TurboPlex pre-mixed or VersaPlex configurable formats for applications including Immuno-Oncology, Tissue Morphology, Lung Cancer, Breast Cancer, and Neurological research), and Miralys Kits (Starter Kits with light box and validation materials, plus Antibody Conjugation Kits allowing customers to create custom probes from 100+ available mass-tag codes). Supporting the reagent business is the MaxOmic Laboratory service offering full-service multiomic spatial imaging and analysis using proprietary software, capable of mapping 300+ lipids/metabolites, 100+ targeted proteins, 12+ targeted transcripts, and small molecule drugs on the same sample. Complementary technology platforms include Bead-AMS for proteome-wide drug screening and PC-PURE for photo-affinity biomarker enrichment. All products work in combination with Bruker MALDI mass spectrometry instrumentation (rapifleX and timsTOF fleX systems).

Differentiator

Problem solved

Functional benefit

Brands

• MaxOmic Laboratory: AmberGen's full-service laboratory providing cutting-edge multiomic spatial biology techniques for imaging a wide range of molecules and cells in their native tissue environment.
• Miralys
• TurboPlex
• VersaPlex
• PCMT (Photocleavable Mass Tag)
• PC-Linker

Products and services

• Miralys Probes Patented photocleavable mass-tag antibody probes that are the core of the Miralys imaging system. Standard fully-validated probes are available for next-day shipment, with optional dual-label probes incorporating both a photocleavable mass tag and a fluorophore for correlative fluorescence and MALDI-MS imaging.
• Miralys Panels Ready-to-use curated collections of Miralys antibody imaging probes available in TurboPlex (pre-mixed, ready-to-use ultra-high-plex) and VersaPlex (individually-supplied configurable) formats. Includes panels for Immuno-Oncology (23-Plex), Tissue Morphology (14-Plex), Lung Cancer (21-Plex), Breast Cancer (20-Plex), Neurological (21-Plex), and Cancer Core (10-Plex).
• Miralys Starter Kit Complete kit including a UV-Photocleavage light box, six-plex panel of probes (Neurology or Immunology tissue type), pre-stained and unstained FFPE tissue slides for validation and training, and all laboratory items needed to implement the Miralys MALDI HiPLEX-IHC workflow. Bundled with pre-staining and post-staining videoconferences with AmberGen Applications Scientists.
• Miralys Antibody Conjugation Kits Kit containing proprietary photocleavable mass tags (PCMTs) and reagents for rapid one-step chemical conjugation of PCMT to customer-chosen antibodies. Over 100 different PCMTs are available for purchase to code antibodies.
• MaxOmic Laboratory Services Full-service laboratory providing access to cutting-edge multiomic spatial biology techniques for imaging a wide range of molecules (proteins, lipids, glycans, metabolites, transcripts) and cells in their native tissue environment using Miralys technology. Maps 300+ lipids/metabolites, 100+ targeted proteins, up to 12 targeted transcripts, and small molecule drugs on the same sample on the same instrument. Delivers results with detailed project reports including descriptive statistics, pairwise colocalization analysis, clustering analysis, and thumbnail grid images.

Quantifiable outcome

• 150+ intact protein biomarkers can be imaged in as fast as 45 minutes per 1 cm² tissue sample, with scan duration independent of multiplexity
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

Partnerships

20 partnerships are on record, tiered supporting, core and minor.

• AbcamsupportingTechnology or IntegrationIHC-validated antibodies from Abcam are available for use in AmberGen's Miralys™ MALDI-IHC Imaging System. Abcam's catalog of validated antibodies expands the range of targets available to Miralys users.
• Cell Signaling Technology (CST)supportingTechnology or IntegrationIHC-validated antibodies from Cell Signaling Technology are available for use in AmberGen's Miralys™ MALDI-IHC Imaging System. CST's validated antibody catalog provides researchers with additional target options for Miralys spatial imaging.
• MTAC at Washington University School of MedicinesupportingImplementation/ SI/ Consulting PartnerThe Mass Spectrometry Technology Access Center (MTAC) at the McDonnell Genome Institute at Washington University School of Medicine provides MALDI-IHC Imaging services using AmberGen's Miralys technology. This is a turnkey service option for first-time Miralys users who need data rapidly, such as for grant submissions.
• TU Wien Research Group for Mass Spectrometric Bio- and Polymer AnalysissupportingImplementation/ SI/ Consulting PartnerThe TU Wien Research Group in Vienna, Austria provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving the European research community.
• UT Austin Mass Spec Imaging FacilitysupportingImplementation/ SI/ Consulting PartnerThe University of Texas at Austin Mass Spec Imaging Facility provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving researchers in the Texas and surrounding regions.
• Proteomics Centre at University of VictoriasupportingImplementation/ SI/ Consulting PartnerThe Proteomics Centre at the University of Victoria in British Columbia, Canada provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving Canadian researchers.
• Filgen (Japan)supportingChannel Partner/ Reseller/ DistributorFilgen is AmberGen's distributor for MALDI-IHC products in Japan, providing local sales, distribution, and customer support for Japanese researchers and institutions.
• MJ Science (Korea)supportingChannel Partner/ Reseller/ DistributorMJ Science is AmberGen's distributor for MALDI-IHC products in Korea, handling local sales and distribution for Korean customers.
• TrendBio (Australia)supportingChannel Partner/ Reseller/ DistributorTrendBio is AmberGen's distributor for MALDI-IHC products in Australia, handling local sales and distribution for Australian customers.
• Verulam Scientific (UK)supportingChannel Partner/ Reseller/ DistributorVerulam Scientific is AmberGen's distributor for MALDI-IHC Starter Kits and Reagents in the UK, handling local sales and distribution for UK customers.
• ScienceExchangesupportingChannel Partner/ Reseller/ DistributorAmberGen's products are available through the ScienceExchange online marketplace, enabling researchers to purchase Miralys reagents through a familiar research procurement platform.
• Scientist.comsupportingChannel Partner/ Reseller/ DistributorAmberGen's products are available through the Scientist.com marketplace, enabling researchers to purchase Miralys reagents through an established scientific procurement platform.
• SomaLogic (now Standard BioTools)coreOEM/ Whitelabel/ Licensing PartnerIn 2011, SomaLogic, Inc. (now Standard BioTools) licensed AmberGen's PC-biotin Phosphoramidite technology for use with its innovative SomaScan® proteomics platform. This licensing agreement enables SomaLogic to use AmberGen's photocleavable reagent in SOMAmer® technology used to discover new biomarkers, representing a long-standing technology licensing relationship.
• Massachusetts General Hospital (MGH)coreStrategic or Co-development PartnerAmberGen collaborated with Massachusetts General Hospital on the discovery of two novel autoantigen biomarkers for Primary Biliary Cirrhosis (PBC): Anti-Kelch-like 12 and Anti-Hexokinase 1. The resulting US Patent 8,852,956 was awarded jointly, and the biomarkers were licensed to INOVA Diagnostics for FDA clearance. The collaboration also included NIH-supported projects on blood-based immunodiagnostics.
• Boston Children's HospitalsupportingStrategic or Co-development PartnerAmberGen collaborated with Boston Children's Hospital on a paper published in PLOS ONE describing application of AmberGen's PC-PURE™ technology to highly multiplex in vitro allergy testing (AllerBead™), using finger-stick blood for multiplex quantification of allergen-specific IgE.
• INOVA DiagnosticssupportingOEM/ Whitelabel/ Licensing PartnerINOVA Diagnostics licensed two novel autoantigen biomarkers for Primary Biliary Cirrhosis (Anti-Kelch-like 12 and Anti-Hexokinase 1) discovered by AmberGen and MGH. Assays based on these biomarkers are currently undergoing FDA clearance. This represents a successful biomarker commercialization partnership.
• PromegasupportingOEM/ Whitelabel/ Licensing PartnerPromega distributes AmberGen's fluorescent tRNA-based protein engineering technology (FluoroTect™ GreenLYS in vitro translation labeling system), representing a product licensing and distribution partnership.
• Thermo Fisher ScientificsupportingOEM/ Whitelabel/ Licensing PartnerThermo Fisher Scientific (through Fisher Scientific) sells AmberGen's PC-Biotin-NHS reagent, representing a product distribution partnership for AmberGen's photocleavable labeling reagents.
• Glen ResearchsupportingOEM/ Whitelabel/ Licensing PartnerGlen Research distributes AmberGen's Photocleavable Phosphoramidite DNA-labeling reagents, representing a product distribution partnership for AmberGen's DNA labeling technology.
• Link Technologies Ltd.minorOEM/ Whitelabel/ Licensing PartnerLink Technologies Ltd. offers AmberGen's Photocleavable Phosphoramidite DNA-labeling reagents in Europe, providing an additional distribution channel for AmberGen's DNA labeling products in the European market.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• 10x Genomics: 10x Genomics offers Xenium in-situ spatial gene expression and Visium spatial transcriptomics platforms targeting tissue-based multiomic profiling — directly competing with AmberGen's Miralys for high-plex spatial biology workflows in pharma and academic research.
• NanoString Technologies (a Bruker company): NanoString's CosMx SMI and GeoMx Digital Spatial Profiling platforms are direct competitors in high-plex spatial tissue imaging — particularly relevant now that NanoString's spatial biology business sits within Bruker, AmberGen's strategic investor and instrument partner.
• Akoya Biosciences: Akoya's Phenoptics (OPAL multiplex immunofluorescence) and PhenoCycler-Fusion platforms compete with Miralys for high-plex tissue biomarker imaging in immuno-oncology and tumor microenvironment profiling.

Emerging players

• Ionpath: Ionpath's MIBI (Multiplexed Ion Beam Imaging) platform provides high-plex spatial proteomics using secondary ion mass spectrometry — a partial overlap with AmberGen's MALDI-MS-based Miralys approach for tissue biomarker imaging.
• Lunaphore: Lunaphore's COMET platform delivers sequential multiplex immunofluorescence for high-plex tissue imaging — emerging competition in the same translational research and clinical pathology segment that Miralys targets.
• Canopy Biosciences: Canopy's Cell DIVE and ChipCytometry platforms offer high-plex spatial tissue imaging — addressing similar tumor microenvironment and neuroscience applications as AmberGen's Miralys panels.
• Resolve Biosciences: Resolve's Molecular Cartography platform provides subcellular spatial transcriptomics, targeting the same pharma translational research segment as Miralys but with a transcriptomics-led workflow.

Broad incumbents

• Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion Imaging System for mass cytometry-based spatial tissue imaging and operates the SomaScan proteomics platform — the latter uses AmberGen's licensed PC-biotin phosphoramidite chemistry, making them both a licensee and adjacent competitor.
• Bruker Corporation: Bruker is both AmberGen's strategic minority investor and the manufacturer of the rapifleX and timsTOF fleX MALDI-MS instruments on which Miralys depends — making it an indispensable partner and a broader incumbent in spatial biology mass spectrometry.
• Miltenyi Biotec: Miltenyi's MACSima and MACS Spatial Tissue Imaging platforms compete in automated high-plex immunofluorescence spatial biology, serving overlapping immuno-oncology and translational research customers as AmberGen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ambergen

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmberGen